The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients.

Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim.

With its lead candidate in a phase 3 trial for a rare eye cancer, Aura Biosciences is looking to expand the drug into a more common disease: bladder cancer.

Just as Smita Gopinath, Ph.D., was setting up her microbiology and immunology lab at Harvard T.H. Chan School of Public Health, the COVID-19 pandemic struck and shut things down. With no lab space or animal facility to house mice she could work with, Gopinath adapted to do whatever research she could.

Noema Pharma has racked up a phase 2a win for its Tourette syndrome drug candidate, reporting hits on the primary and key secondary endpoints in a small study of the former Roche molecule.

Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra Biosciences.

Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading for the exits along with a swath of the company’s leadership.

Johnson & Johnson is jettisoning several programs, with three of the culls taking place in the neuroscience field.

Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Novo Nordisk’s Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) and body weight in a phase 2 trial in patients with type 2 diabetes, the company announced in an Oct. 15 release.

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy.